# A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

> **NCT02927301** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 181 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody

## Key facts

- **NCT ID:** NCT02927301
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-20
- **Primary completion:** 2020-05-07
- **Final completion:** 2023-09-05
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02927301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02927301, "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02927301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*